| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444380 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
This phase I-IIa study suggests that BMS-690514 has manageable safety profile and antitumour activity in patients with NSCLC at 200Â mg/d, including those with EGFR mutations conferring resistance to erlotinib.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jean-Charles Soria, José Baselga, Nasser Hanna, Scott A. Laurie, Rastislav Bahleda, Enriqueta Felip, Emiliano Calvo, Jean-Pierre Armand, Frances A. Shepherd, Christopher T. Harbison, David Berman, Jong-Soon Park, Steven Zhang, Blisse Vakkalagadda,